- Home
- BTAI vs ICU Comparison
BTAI vs ICU Comparison
Compare BTAI & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- ICU
- Stock Information
- Founded
- BTAI 2017
- ICU 2018
- Country
- BTAI United States
- ICU United States
- Employees
- BTAI N/A
- ICU N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- ICU Biotechnology: Pharmaceutical Preparations
- Sector
- BTAI Health Care
- ICU Health Care
- Exchange
- BTAI Nasdaq
- ICU Nasdaq
- Market Cap
- BTAI 10.7M
- ICU 10.4M
- IPO Year
- BTAI 2018
- ICU N/A
- Fundamental
- Price
- BTAI $1.46
- ICU $1.24
- Analyst Decision
- BTAI Buy
- ICU
- Analyst Count
- BTAI 5
- ICU 0
- Target Price
- BTAI $42.60
- ICU N/A
- AVG Volume (30 Days)
- BTAI 97.3K
- ICU 115.6K
- Earning Date
- BTAI 05-12-2025
- ICU 05-14-2025
- Dividend Yield
- BTAI N/A
- ICU N/A
- EPS Growth
- BTAI N/A
- ICU N/A
- EPS
- BTAI N/A
- ICU N/A
- Revenue
- BTAI $1,852,000.00
- ICU $135,000.00
- Revenue This Year
- BTAI $41.00
- ICU $648.15
- Revenue Next Year
- BTAI $197.21
- ICU $100.00
- P/E Ratio
- BTAI N/A
- ICU N/A
- Revenue Growth
- BTAI 5.47
- ICU N/A
- 52 Week Low
- BTAI $1.29
- ICU $1.11
- 52 Week High
- BTAI $42.08
- ICU $13.85
- Technical
- Relative Strength Index (RSI)
- BTAI 37.90
- ICU 37.68
- Support Level
- BTAI $1.34
- ICU $1.22
- Resistance Level
- BTAI $1.64
- ICU $1.30
- Average True Range (ATR)
- BTAI 0.15
- ICU 0.06
- MACD
- BTAI -0.01
- ICU 0.02
- Stochastic Oscillator
- BTAI 16.56
- ICU 33.33
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.